PCRX
Price
$25.84
Change
+$0.45 (+1.77%)
Updated
Aug 22 closing price
Capitalization
1.16B
67 days until earnings call
RGC
Price
$12.80
Change
+$0.24 (+1.91%)
Updated
Aug 22 closing price
Capitalization
6.33B
Interact to see
Advertisement

PCRX vs RGC

Header iconPCRX vs RGC Comparison
Open Charts PCRX vs RGCBanner chart's image
Pacira BioSciences
Price$25.84
Change+$0.45 (+1.77%)
Volume$453.14K
Capitalization1.16B
Regencell Bioscience Holdings
Price$12.80
Change+$0.24 (+1.91%)
Volume$165.37K
Capitalization6.33B
PCRX vs RGC Comparison Chart in %
Loading...
PCRX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RGC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
PCRX vs. RGC commentary
Aug 24, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is PCRX is a Buy and RGC is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 24, 2025
Stock price -- (PCRX: $25.84 vs. RGC: $12.80)
Brand notoriety: PCRX and RGC are both not notable
Both companies represent the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: PCRX: 71% vs. RGC: 13%
Market capitalization -- PCRX: $1.16B vs. RGC: $6.33B
PCRX [@Pharmaceuticals: Generic] is valued at $1.16B. RGC’s [@Pharmaceuticals: Generic] market capitalization is $6.33B. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $69.41B to $0. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $3.84B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

PCRX’s FA Score shows that 0 FA rating(s) are green whileRGC’s FA Score has 0 green FA rating(s).

  • PCRX’s FA Score: 0 green, 5 red.
  • RGC’s FA Score: 0 green, 5 red.
According to our system of comparison, PCRX is a better buy in the long-term than RGC.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

PCRX’s TA Score shows that 5 TA indicator(s) are bullish while RGC’s TA Score has 3 bullish TA indicator(s).

  • PCRX’s TA Score: 5 bullish, 5 bearish.
  • RGC’s TA Score: 3 bullish, 3 bearish.
According to our system of comparison, both PCRX and RGC are a good buy in the short-term.

Price Growth

PCRX (@Pharmaceuticals: Generic) experienced а +4.28% price change this week, while RGC (@Pharmaceuticals: Generic) price change was -2.44% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was +60.15%. For the same industry, the average monthly price growth was +10.62%, and the average quarterly price growth was +74.68%.

Reported Earning Dates

PCRX is expected to report earnings on Oct 30, 2025.

Industries' Descriptions

@Pharmaceuticals: Generic (+60.15% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
RGC($6.33B) has a higher market cap than PCRX($1.16B). RGC YTD gains are higher at: 9746.075 vs. PCRX (37.155). PCRX has higher annual earnings (EBITDA): -1.3M vs. RGC (-3.99M). PCRX has more cash in the bank: 446M vs. RGC (2.96M). RGC has less debt than PCRX: RGC (85.7K) vs PCRX (631M). PCRX has higher revenues than RGC: PCRX (706M) vs RGC (0).
PCRXRGCPCRX / RGC
Capitalization1.16B6.33B18%
EBITDA-1.3M-3.99M33%
Gain YTD37.1559746.0750%
P/E Ratio12.90N/A-
Revenue706M0-
Total Cash446M2.96M15,062%
Total Debt631M85.7K736,289%
FUNDAMENTALS RATINGS
PCRX vs RGC: Fundamental Ratings
PCRX
RGC
OUTLOOK RATING
1..100
2818
VALUATION
overvalued / fair valued / undervalued
1..100
58
Fair valued
95
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
95100
PRICE GROWTH RATING
1..100
4334
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

PCRX's Valuation (58) in the Pharmaceuticals Other industry is somewhat better than the same rating for RGC (95) in the Movies Or Entertainment industry. This means that PCRX’s stock grew somewhat faster than RGC’s over the last 12 months.

PCRX's Profit vs Risk Rating (100) in the Pharmaceuticals Other industry is in the same range as RGC (100) in the Movies Or Entertainment industry. This means that PCRX’s stock grew similarly to RGC’s over the last 12 months.

PCRX's SMR Rating (95) in the Pharmaceuticals Other industry is in the same range as RGC (100) in the Movies Or Entertainment industry. This means that PCRX’s stock grew similarly to RGC’s over the last 12 months.

RGC's Price Growth Rating (34) in the Movies Or Entertainment industry is in the same range as PCRX (43) in the Pharmaceuticals Other industry. This means that RGC’s stock grew similarly to PCRX’s over the last 12 months.

RGC's P/E Growth Rating (100) in the Movies Or Entertainment industry is in the same range as PCRX (100) in the Pharmaceuticals Other industry. This means that RGC’s stock grew similarly to PCRX’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
PCRXRGC
RSI
ODDS (%)
Bearish Trend 3 days ago
70%
N/A
Stochastic
ODDS (%)
Bearish Trend 3 days ago
79%
Bullish Trend 3 days ago
86%
Momentum
ODDS (%)
Bullish Trend 3 days ago
70%
Bearish Trend 3 days ago
90%
MACD
ODDS (%)
Bullish Trend 3 days ago
68%
Bullish Trend 3 days ago
82%
TrendWeek
ODDS (%)
Bullish Trend 3 days ago
65%
Bearish Trend 3 days ago
90%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
69%
Bearish Trend 3 days ago
89%
Advances
ODDS (%)
Bullish Trend 3 days ago
69%
Bullish Trend 3 days ago
84%
Declines
ODDS (%)
Bearish Trend 10 days ago
78%
Bearish Trend 5 days ago
90%
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
78%
N/A
Aroon
ODDS (%)
Bearish Trend 3 days ago
88%
Bearish Trend 3 days ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
PCRX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RGC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
SHDRX10.340.30
+2.99%
American Beacon Shapiro SMID Cap Eq R6
CEIIX14.190.29
+2.09%
Manning & Napier Callodine Equity Inc I
JDVRX24.190.38
+1.60%
PGIM Jennison Value R
AICRX38.910.60
+1.57%
American Century Discplnd Cor Val R
FECMX44.610.64
+1.46%
Fidelity Advisor Emerging Markets I

PCRX and

Correlation & Price change

A.I.dvisor tells us that PCRX and ALKS have been poorly correlated (+32% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that PCRX and ALKS's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PCRX
1D Price
Change %
PCRX100%
+1.77%
ALKS - PCRX
32%
Poorly correlated
+2.37%
ELAN - PCRX
32%
Poorly correlated
+2.40%
COLL - PCRX
29%
Poorly correlated
-1.04%
TEVA - PCRX
28%
Poorly correlated
-1.81%
ETON - PCRX
27%
Poorly correlated
+1.23%
More

RGC and

Correlation & Price change

A.I.dvisor tells us that RGC and QNTM have been poorly correlated (+21% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that RGC and QNTM's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RGC
1D Price
Change %
RGC100%
+1.91%
QNTM - RGC
21%
Poorly correlated
+0.19%
SBFM - RGC
20%
Poorly correlated
-1.41%
ANIP - RGC
11%
Poorly correlated
-0.14%
PCRX - RGC
11%
Poorly correlated
+1.77%
CPIX - RGC
8%
Poorly correlated
+1.54%
More